血管炎治療市場：薬剤タイプ、疾患タイプ、流通チャネル別-2025～2030年の世界予測

血管炎治療市場は、2023年に1億9,308万米ドルと評価され、2024年には2億292万米ドルに達すると予測され、CAGR 5.21％で成長し、2030年には2億7,553万米ドルに達すると予測されています。

血管炎治療には、血管の炎症を特徴とする疾患群の管理が含まれ、さまざまな臓器に影響を及ぼし、生命を脅かす合併症を引き起こす可能性があります。血管炎治療の必要性は、臓器障害を予防し、患者のQOLを維持することが極めて重要であることから強調されています。血管炎治療の用途は、免疫抑制療法から炎症の制御と関連症状の軽減を目的とした生物製剤まで多岐にわたり、最終用途は主に病院、専門クリニック、研究機関などです。血管炎治療市場は、自己免疫疾患の有病率の上昇、診断技術の進歩、この疾患に対する意識の高まりによって大きな成長を遂げています。主要影響要因としては、世界人口の高齢化、遺伝的素因、医療サービスへのアクセス向上などが挙げられます。しかし、高額な治療費、免疫抑制剤の長期使用に伴う副作用、稀な血管炎性疾患の診断の複雑さなどの課題も残っています。

特定の免疫経路を標的とし、副作用を最小限に抑えながら治療効果を高める新規治療法の開発には多くの機会があります。モノクローナル抗体や個別化医療といったバイオ医薬品のイノベーションは、アンメット・メディカル・ニーズへの対応に有望な道を示しています。研究開発や戦略的パートナーシップに投資している企業は、こうした開発を活用するのに有利な立場にあります。とはいえ、規制上のハードルや新たな治療法を検証するための長期臨床検査の必要性など、限界もあります。診断基準の改良や早期発見のためのバイオマーカーの発見を目指す学際的な研究に注力することが、事業の成長につながると考えられます。

市場開拓者にとっては、標的治療や非侵襲的診断ツールの開発など、患者管理を一変させ、医療コストを削減できる革新的なセグメントが含まれます。さらに、共同研究、合併、買収によって特徴づけられる競合情勢に関する考察は、市場参入と拡大のための戦略的指針を記載しています。患者中心のアプローチを理解し、新たな医療技術を活用することで、この進化する市場における競争優位性をさらに促進することができると考えられます。まとめると、血管炎治療市場には大きな機会がある一方で、成長の可能性を最大化するためには複雑な課題を克服する必要があるということです。

市場力学：急速に進化する血管炎治療市場における主要市場洞察の解明

血管炎治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 血管炎の罹患率と有病率の上昇
  • 効率的な診断のための画像技術や血清学的検査の利用の増加
  • 血管炎に関する認識を広めるための取り組み
• 市場抑制要因
  • 血管炎の治療に伴う高コスト
• 市場機会
  • 遺伝子プロファイリングと標的治療の重視
  • 新規治療開発のための継続的研究
• 市場課題
  • 血管炎治療に関連する副作用と安全性への懸念

ポーターのファイブフォース：血管炎治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血管炎治療市場における外部からの影響の把握

外部マクロ環境要因は、血管炎治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：血管炎治療市場における競合情勢の把握

血管炎治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：血管炎治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血管炎治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：血管炎治療市場における成功への道筋を描く

血管炎治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 血管炎の発生率と有病率の上昇
    • 効率的な診断のための画像技術と血清学的検査の利用の増加
    • 血管炎に関する啓発活動
  • 抑制要因
    • 血管炎の治療にかかる高額な費用
  • 機会
    • 遺伝子プロファイリングと標的治療に重点を置く
    • 新しい治療法の開発に向けた継続的な研究
  • 課題
    • 血管炎治療に関連する副作用と安全性の懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 血管炎治療市場：薬剤タイプ別

• イントロダクション
• 生物製剤
• コルチコステロイド
• 免疫抑制剤

第7章 血管炎治療市場：疾患タイプ別

• イントロダクション
• 大型血管炎
• 小・中型血管炎

第8章 血管炎治療市場：流通チャネル別

• イントロダクション
• ドラッグストアと薬局
• 病院薬局
• オンライン薬局

第9章 南北アメリカの血管炎治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の血管炎治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの血管炎治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals, Inc.
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bristol Myers Squibb Company
• DAIICHI SANKYO COMPANY, LIMITED
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Grifols, S.A.
• InflaRx GmbH
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• UCB S.A.
• Vifor Fresenius Medical Care Renal Pharma

LIST OF FIGURES

• FIGURE 1. VASCULITIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. VASCULITIS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VASCULITIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VASCULITIS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY LARGE VESSEL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SMALL & MEDIUM VESSEL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DRUG STORE & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Vasculitis Treatment Market was valued at USD 193.08 million in 2023, expected to reach USD 202.92 million in 2024, and is projected to grow at a CAGR of 5.21%, to USD 275.53 million by 2030.

Vasculitis treatment encompasses the management of a group of disorders characterized by inflammation of blood vessels, which can affect various organs and lead to potentially life-threatening complications. The necessity of vasculitis treatment is underscored by the critical need to prevent organ damage and maintain patient quality of life. Applications of vasculitis treatments range from immunosuppressive therapies to biologic agents aimed at controlling inflammation and reducing associated symptoms, while end-use scope primarily includes hospitals, specialty clinics, and research institutions. The market for vasculitis treatment is witnessing significant growth driven by the rising prevalence of autoimmune disorders, advancements in diagnostic technologies, and increasing awareness about the condition. Key influencing factors include an aging global population, genetic predispositions, and improved access to healthcare services. However, challenges persist, such as high treatment costs, side effects associated with long-term use of immunosuppressive drugs, and the complexity of diagnosing rare vasculitic conditions.

Opportunities abound in the development of novel therapies that target specific immune pathways, enhancing treatment efficacy while minimizing adverse effects. Biopharmaceutical innovations, such as monoclonal antibodies and personalized medicine, present promising avenues for addressing unmet medical needs. Companies investing in R&D and strategic partnerships are well-positioned to capitalize on these developments. Nevertheless, limitations include regulatory hurdles and the need for long-term clinical trials to validate new treatment modalities. Business growth will benefit from focusing on interdisciplinary research that aims to refine diagnostic criteria and discover biomarkers for early detection.

For market players, areas of innovation include developing targeted therapies and non-invasive diagnostic tools, which could transform patient management and reduce healthcare costs. Furthermore, insights into the competitive landscape-characterized by collaborations, mergers, and acquisitions-offer strategic guidance for market entry and expansion. Understanding patient-centric approaches and leveraging emerging health technologies could further facilitate competitive advantage in this evolving market. In summary, while the vasculitis treatment market presents substantial opportunities, it also requires navigating complex challenges to maximize growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vasculitis Treatment Market

The Vasculitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence and prevalence of vasculitis
  • Increasing use of imaging technologies and serological tests for efficient diagnosis
  • Initiatives to spread awareness regarding vasculitis
• Market Restraints
  • High cost associated with the treatment of vasculitis
• Market Opportunities
  • Emphasis on genetic profiling and targeted therapies
  • Ongoing research for development of novel therapeutics
• Market Challenges
  • Adverse effects and safety concerns associated with vasculitis treatment

Porter's Five Forces: A Strategic Tool for Navigating the Vasculitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vasculitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vasculitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vasculitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vasculitis Treatment Market

A detailed market share analysis in the Vasculitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vasculitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vasculitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vasculitis Treatment Market

A strategic analysis of the Vasculitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vasculitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Grifols, S.A., InflaRx GmbH, Merck & Co., Inc., Novartis AG, Pfizer Inc., UCB S.A., and Vifor Fresenius Medical Care Renal Pharma.

Market Segmentation & Coverage

This research report categorizes the Vasculitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Biologics, Corticosteroids, and Immunosuppressants.
• Based on Disease Type, market is studied across Large Vessel Vasculitis and Small & Medium Vessel Vasculitis.
• Based on Distribution Channel, market is studied across Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence and prevalence of vasculitis
    • 5.1.1.2. Increasing use of imaging technologies and serological tests for efficient diagnosis
    • 5.1.1.3. Initiatives to spread awareness regarding vasculitis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the treatment of vasculitis
  • 5.1.3. Opportunities
    • 5.1.3.1. Emphasis on genetic profiling and targeted therapies
    • 5.1.3.2. Ongoing research for development of novel therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects and safety concerns associated with vasculitis treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vasculitis Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Corticosteroids
• 6.4. Immunosuppressants

7. Vasculitis Treatment Market, by Disease Type

• 7.1. Introduction
• 7.2. Large Vessel Vasculitis
• 7.3. Small & Medium Vessel Vasculitis

8. Vasculitis Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Drug store & Retail Pharmacies
• 8.3. Hospital Pharmacies
• 8.4. Online Pharmacies

9. Americas Vasculitis Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Vasculitis Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Vasculitis Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Amneal Pharmaceuticals, Inc.
• 4. Bayer AG
• 5. Bio-Rad Laboratories, Inc.
• 6. Boehringer Ingelheim Pharmaceuticals, Inc.
• 7. Bristol Myers Squibb Company
• 8. DAIICHI SANKYO COMPANY, LIMITED
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline PLC
• 11. Grifols, S.A.
• 12. InflaRx GmbH
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. UCB S.A.
• 17. Vifor Fresenius Medical Care Renal Pharma